Sun Pharma recovered partially from the day's low of Rs 1,070, and finally ended 12% lower at Rs 1,140. The counter registered heavy volumes of around 580,400 shares, which is around 30-times higher than its two-week daily average volume of around 19,230 shares on the BSE.
______________________________________________________
( Updated at 1203 hrs)
Sun Pharma crashed in opening trades following news of US FDA seizing all drugs by subsidiary Caraco.
Sun Pharma opened with a loss of 7.6% at Rs 1,199. It nosedived over 17% to touch the day's low of Rs 1,070.
The stock has recovered partially and is now trading 12% lower at Rs 1,144. The counter has witnessed 21-fold increase in trading volumes at 403,752 shares from its two-week daily traded average of 19,233 shares on the BSE.
US Food and Drug Administration has seized all drugs made by Caraco on charges of repeated violations of manufacturing standards and plans to stop it from distributing drugs until they follow requirements. Sun Pharma has a majority stake in Caraco.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
